Yes, you can continue taking your GLP-1 receptor agonist while on antibiotics for an infected abscess.
There is no contraindication or clinically significant interaction between GLP-1 receptor agonists and antibiotics used to treat infected abscesses, and continuing the medication maintains important metabolic benefits without compromising infection treatment.
Key Evidence Supporting Continuation
The FDA labels for both semaglutide 1 and liraglutide 2 do not list active infections or concurrent antibiotic use as contraindications or warnings. The only absolute contraindications are:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to the drug
Why This Matters for Your Situation
Metabolic stability during infection is crucial. The 2025 multidisciplinary consensus statement emphasizes that stopping GLP-1 receptor agonists can lead to peri-operative hyperglycemia, which is associated with increased surgical site infections, acute kidney injury, and prolonged hospital stays 3. While this guideline addresses surgical contexts, the principle applies to any acute illness: maintaining glycemic control during infection reduces complications.
GLP-1 agonists may actually improve infection outcomes. Recent evidence suggests potential benefits:
- A 2025 population study found that semaglutide improved Helicobacter pylori eradication rates to 93.8% compared to 83.7% without GLP-1 therapy (OR 2.78, p=0.007) 4
- A 2026 network meta-analysis of 219,283 participants found no increased risk of sepsis, abscess, gangrene, or other infections with GLP-1 receptor agonists 5
- Experimental data suggests liraglutide may attenuate sepsis through gut microbiota modulation 6
Practical Considerations
Drug-drug interactions are minimal. A 2012 review found that GLP-1 receptor agonists primarily affect the absorption kinetics (Cmax and Tmax) of oral medications due to delayed gastric emptying, but do not significantly alter total drug exposure (AUC) for most medications 7. Since antibiotics for abscesses are typically:
- Given intravenously (bypassing gastric effects entirely), or
- Oral antibiotics where steady-state levels matter more than peak timing
The delayed gastric emptying effect is clinically irrelevant for infection treatment.
Monitor for gastrointestinal symptoms. GLP-1 agonists commonly cause nausea, vomiting, and diarrhea 8. If you develop severe GI symptoms while on antibiotics, distinguish between:
- Expected GLP-1 side effects (usually mild, occur early in treatment)
- Antibiotic-related GI upset (Clostridium difficile colitis if severe diarrhea develops)
- Worsening infection requiring surgical intervention
When to Reconsider
Temporarily hold the GLP-1 agonist only if:
- You require urgent surgical drainage of the abscess (follow peri-operative guidelines: hold for 1 week for weekly formulations like semaglutide) 9
- You develop severe nausea/vomiting preventing oral intake and adequate hydration
- You develop acute pancreatitis (rare but requires immediate discontinuation per FDA labeling) 1, 2
Resume immediately after any temporary hold once you can tolerate oral intake and the acute surgical period has passed.
Bottom Line Algorithm
- Continue GLP-1 agonist during antibiotic treatment for abscess
- Monitor glucose if you have diabetes (infection can raise blood sugar)
- Stay hydrated (both infection and GLP-1 agonists can cause dehydration)
- Hold only if requiring urgent surgery, then resume post-operatively
- Contact your provider if severe abdominal pain, persistent vomiting, or signs of worsening infection develop
The evidence strongly supports continuation, as stopping provides no infection-related benefit while potentially compromising metabolic control during physiologic stress.